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Abstract 
Complementary medicines are accepting world-wide and are used extensively due to its safe and non-toxic nature. The 
aim of the study was to evaluate the immunomodulatory potential of the Biofield Energy Treated (known as The Trivedi 
Effect®) novel proprietary formulation and Biofield Energy Treatment per se on male rats. The formulation was divided 
into two parts, one part was defined as the untreated test formulation, while the other part was treated with the Biofield 
Energy by Mahendra Kumar Trivedi and denoted as the Biofield Energy Treated test formulation. Experimental groups 
(G) included G1 with normal control, G2 with disease control, G3 with the treatment of levamisole (positive control), G4 
with untreated test formulation, G5 received Biofield Treated test formulation, G6 consisted of Biofield Energy Treatment 
per se to animals (-15 days), G7 received Biofield Treated test formulation from day -15, G8 has received Biofield Energy 
Treatment per se to animals along with Biofield Treated test formulation from day -15, and G9 received Biofield Energy 
Treatment per se to animals with the untreated test formulation. 
The results showed that primary antibody titer value was significantly increased by 60%, 63.33%, 33.33%, and 20% in 
the G6, G7, G8, and G9 groups, respectively compared with the G2. However, secondary antibody titer values were 
significantly increased by 50%, 37.5%, 37.5%, and 12.5% in the G6, G7, G8, and G9 groups, respectively compared with 
the G2. Delayed type hypersensitivity (DTH) reaction showed significant increase level of rat paw volume by 86.36%, 
30.68%, and 14.77% in the G5, G6, and G7 groups, respectively compared with the G2. Additionally, the platelet count 
was significantly increased by 11.96% in G6 compared to G2. The level of uric acid was significantly reduced by 64.29% 
in G7 compared to G2. Further, levels of calcium and phosphorous were significantly increased by 19.16% and 14.92%, 
respectively in the G9 compared to the G2.  
Moreover, the level of magnesium was significantly increased by 13.11% and 10.66% in G4 and G9 groups, respectively 
compared to G2. Overall, data suggests that the Biofield Treatment per se (The Trivedi Effect®) and Biofield Treated test 
formulation have shown significant immunomodulatory action as compared with the untreated product and unblessed 
rats. Therefore, the Biofield Treatment could be utilised against various immuno-related disorders such as neutropenia, 
asplenia, trauma, sickle cell anemia, multiple myeloma, chronic lymphoid leukemia, stress, aging, etc. 
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Abbreviations: DTH: Delayed Type Hypersensitivity; 
CAM: Complementary and Alternative Medicine; RBC: Red 
Blood Count; DTH: Delayed Type Of Hypersensitivity; 
PBS: Phosphate-Buffered Saline; MCH: Mean Corpuscular 
Hemoglobin; MCV: Corpuscular Volume; PCV: Packed Cell 
Volume; MCHC: Mean Corpuscular Hemoglobin 
Concentration; BUN: Blood Urea Nitrogen; UA: Creatinine, 
Uric Acid; SEM: Standard Error of Mean; HA: 
Haemagglutination; MCV: Mean Corpuscle Volume. 
 
Introduction 
Inflammation plays a central mechanism and vital role in 
most of the existing chronic illnesses, such as 
neurodegenerative, cardiovascular, pulmonary, metabolic, 
autoimmune and neoplastic diseases. However, 
inflammation is a kind of localized protective response 
which is elicited by any injury or tissue destruction that 
helps to destroy, dilute or sequester the source of 
injurious agent and the injured tissue. Inflammation is the 
complex reaction and is closely related with the repair 
process through native parenchymal cells regeneration, 
by filling the defect with the fibrous tissue. 
Immunomodulators are the agents which regulate the 
immune system in various dysfunctions, while most of 
them are based on various medicinal plants and minerals 
[1]. These minerals based formulations are believed to 
improve the immune system by sustaining the body self-
defense mechanism and re-establish the body’s 
equilibrium. Literature data suggest that most of the 
immunomodulatory formulations are based on medicinal 
plants, minerals, and organic matter [2]. Herbal based 
products have wide activity due to its lavish chemical and 
structural diversity with broad spectrum activities. 
Besides, minerals and plant based product have reported 
with limited and low toxicity that make them ideal 
moieties for the different types of drug formulations [3]. 
Herbal based medicines, trace minerals like selenium, 
zinc, copper, magnesium, etc. have been reported for their 
immunomodulatory activity [4]. In this study, a novel 
proprietary formulation was designed which contained 
nanocurcumin, zinc chloride, magnesium (II) gluconate 
hydrate, sodium selenate, ascorbic acid (Vit-C), 
cholecalciferol (Vit-D3), iron (II) sulfate, and copper 
chloride. It might be expected about coordinated 
interactions of all the constituents with the immune cells 
that can evoke an appropriate immune response. All the 
individual constituents of this formulation has been 
shown different biological activities such as antioxidant, 
anti-inflammatory, anti-viral, and immune modulating [5]. 
Besides, curcumin has also been reported with its 
inhibitory potential to the cellular proliferation and 
cytokine production by inhibiting the NF-kappaB target 
genes. It plays important role in treatment of 
inflammation and metabolic diseases [6]. 
Biofield Energy is considered as a complementary and 
alternative medicine (CAM) has been reported with an 
improved immune response with several advantages in 
various forms [7]. Researchers reported on the basis of 
several clinical trials, the importance of Biofield Energy 
Healing on immune system such as in case of improved 
immune function in cervical cancer patients after 
therapeutic touch [8] and massage therapy [9]. However, 
this energy can exists in various forms that can be 
harnessed and transmit it into living and non-living things 
by the process of Biofield Energy Treatment. The Trivedi 
Effect® had been expansively reported with significant 
results in different scientific fields like cancer research 
[10, 11], microbiology [12-15], genetics [16-17], 
pharmaceutical science [18-21], agricultural science [22-
25], and materials science [26-29]. Thus, the present 
study has been designed to evaluate the impact of the 
Biofield Treated formulation and Biofield Energy 
Treatment per se immunomodulatory effect such as the 
primary and secondary humoral immune response, 
delayed type hypersensitivity reaction, hematology and 
biochemical parameters. 
  
Materials and Methods 
Chemicals and reagents 
Cyclophosphamide, carboxymethylcellulose sodium were 
purchased from Sigma Chemical Co. (St. Louis, MO). 
Nanocurcumin (purity 40%) was procured from Sanat 
Products Ltd., India. Zinc chloride and magnesium (II) 
gluconate hydrate procured from TCI, Japan. Sodium 
selenate procured from Alfa Aesar, USA. Levamisole 
hydrochloride, ascorbic acid, cholecalciferol and iron (II) 
sulfate were procured from Sigma, USA. Copper Chloride 
was purchased from VETEC (Sigma-Aldrich), USA. Rest of 
chemicals were used in the study of analytical grade 
available from India. 
 
 Laboratory animals 
A total number of 72 healthy Wistar male rats (200-275 
grams; 8 animals in each groups) were used in this 
experiment. Animals were maintained under standard 
experimental conditions, with room temperature (22 ± 
3°C) and relative humidity (30% to 70%). The animals 
were acclimatized prior to the experiments, and all were 
accessed once daily for clinical signs, behaviors, morbidity 
and mortality. The animal care was complied with the 
Regulations of CPCSEA. The test facility was registered for 
experiment of animals. The animals were procured using 
Animal Ethics Committee approved protocol) and the 
husbandry conditions maintained as per CPCSEA 
recommendations.  
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Biofield energy treatment strategy 
The test item was divided into two parts. One part was 
considered as untreated test formulation, where no 
Biofield Energy Treatment was provided, while the 
untreated group was treated with “sham” healer for 
comparison purposes. The “sham” healer did not have any 
knowledge about the Biofield Energy Treatment. Besides, 
the second part was received Biofield Energy Treatment 
(The Trivedi Effect®) by renowned healer Mahendra 
Kumar Trivedi remotely under standard laboratory 
conditions for ~3 minutes through his unique energy 
transmission process. Besides, three group of animals 
were also received Biofield Energy Treatment under 
laboratory conditions for ~3 minutes. After Biofield 
Energy Treatment, both the Biofield Treated and 
untreated samples were returned in the similar sealed 
condition and used as per the study plan. 
 
 Antigen (Sheep RBC) 
The blood was removed from the jugular vein of a healthy 
sheep aseptically and transferred in a heparinized tube. 
Erythrocytes were isolated from plasma by centrifugation 
(800 g, 10ºC, 10 minutes), washed two-times with the 
normal saline (NS) and then further diluted in NS and the 
samples were analyzed using Hematology analyzer 
(Abbott Model-CD-3700). Depending on the number of 
erythrocytes present in the sample was further diluted 
(using NS) prior injecting to the rat [30]. 
 
Treatment regimen 
The animals were grouped (G) after one week of 
acclimatization according to their body weight. Normal 
control (G1) group was given 0.5% oral suspension of 
carboxymethylcellulose-sodium. All the animals except G1 
group were received cyclophosphamide (at 25 mg/kg; 
i.p.) on day 9 and 16. G1, G2 and G6 were treated with 
0.5% w/v CMC-Na in distilled water. G3 animals received 
reference item, levamisole hydrochloride at 50 mg/kg 
from day 1 to 22. G4 and G5 groups received the 
untreated and Biofield Energy Treated test formulation 
(at 624.115 mg/kg, p.o.). Moreover, G6 and G8 groups 
included Biofield Energy Treatment per se to the animals 
(-15 days). After 15 day pre-study period (G7 and G8 
animals received test formulation from day -15), while G9 
group animals were treated with Biofield Energy 
Treatment per se along with untreated test formulation 
for 22 days. On day 7, all the animals in except G1 were 
challenged with sheep red blood cells (sRBC) at 0.5 X 
109/100 gm; i.p. to sensitize the immunological response. 
On day 14th, blood was collected from retro-orbital plexus 
and serum was separated for hemagglutination test for 
humoral immune response. On day 21st, the animals were 
challenged with sRBC (0.5 X 109 cells/50µL/rat) in sub-
planter region and after 24 hours, paw volume was 
measured to evaluate cellular immune response. At the 
end of the experiment, blood samples were collected and 
subjected to hematology and biochemical parameters. 
 
Determination of humoral immune response 
About 25 μL of serum was serially diluted with 25 μL of 
NS. Then, the sRBC was added to each dilutions and 
incubated for one hour at 37ºC. The rank of minimum 
dilution that exhibited hemagglutination was considered 
as an antibody titer. The level of antibody titer on day 14 
was considered as the “primary humoral immune 
response” and the day 21 for “secondary humoral 
immune response” [31]. 
 
 Measurement of paw volume (Delayed Type 
Hypersensitivity) 
The footpad reaction method was used for the evaluation 
of cellular immune response. The edema was induced in 
the right paw of rats by injecting sRBC (0.025 X 109 cells) 
in the sub-plantar region. An increase in the paw volume 
after 24 hours, i.e., on day 21 was measured using digital 
plethysmometer (PanLab, Spain). The increase of mean 
percent of paw volume was considered as delayed type of 
hypersensitivity (DTH) and as an index of cell-mediated 
immunity. The volume of the left hind paw, injected 
similarly with phosphate-buffered saline (PBS) and 
served as negative control. 
 
 Hematological and biochemical parameters  
The animals were fasted for overnight and blood was 
collected from retro-orbital plexus under anaesthesia 
using isoflurane. An aliquot of blood sample from each 
animal was directly subjected for the estimation of 
hematological parameters viz. red blood count (RBC), 
hemoglobin (Hb), platelets, mean corpuscular volume 
(MCV), packed cell volume (PCV), mean corpuscular 
hemoglobin (MCH), and mean corpuscular hemoglobin 
concentration (MCHC) using hematology analyzer (Celltak 
Alpha, Nihon Khoden, Japan) [32]. An aliquot of blood 
sample was used for the isolation of serum and 
determined for biochemical parameters viz. blood urea 
nitrogen (BUN), creatinine, uric acid (UA), calcium, 
magnesium, phosphorus, sodium, potassium, and chloride 
ions using biochemistry analyzer (MISPA NANO, AGAPEE, 
India) [32]. 
 
 Statistical analysis 
Values were expressed as mean ± standard error of mean 
(SEM) and were subjected to Student’s t-test. Statistical 
significance was considered at p≤0.05. 
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Results  
Evaluation of humoral immune response 
The results of primary and secondary humoral immune 
response were presented in terms of haemagglutination 
(HA) titer values after test formulation administration, 
those are summarized in Figure 1. The primary titer value 
in the disease control group (G2) was significantly 
decreased by 79.17% (p<0.001) as compared with the 
normal control (G1) group (18.0 ± 3.29). However, the 
primary HA titer was increased significantly after 
administration of the Biofield Energy Treated test 
formulation in different groups. The animals in the 
Biofield Treated groups showed a significantly improved 
the primary HA titer values by 60%, 63.34%, 33.34%, and 
20% in the G6, G7, G8, and G9, respectively as compared 
with the disease control group (G2). The value of primary 
titer in the levamisole group (positive control, G3) 
showed 9.0 ± 1.0, while it was 7.0 ± 0.65 in the G4 group 
i.e., in the untreated test formulation group. Similarly, the 
increased titer values in the G6, G7, G8, and G9 were 6.0 ± 
0.75, 6.12 ± 0.97, 5.0 ± 0.92, and 4.5 ± 0.5, respectively. 
Besides, the Biofield Treated test formulation showed an 
improved secondary antibody titer level by 6.25%, 50%, 
37.5%, 37.5%, and 12.5% in the G5, G6, G7, G8, and G9, 
groups respectively as compared with the G2 group.  
 
 
 
Figure 1: The effect of the test formulation on primary and secondary humoral immune response in rats. Values are 
expressed as the mean ± SEM. G1: Normal control; G2: Disease control; G3: Levamisole hydrochloride; G4: Untreated 
test formulation; G5: Biofield Treated test formulation; G6: Biofield Energy Treatment per se to animals (-15 days); G7: 
Biofield Treated test formulation from day -15; G8: Biofield Energy Treatment per se to animals with Biofield Treated 
test formulation from day -15; and, G9: Biofield Energy Treatment per se to animals with untreated test formulation. 
 
 
 Measurement of delayed type hypersensitivity 
(DTH) reaction (Paw Volume) 
Effect of the Biofield Treated test formulation with 
respect to DTH reaction in male rats was measured and 
are presented in Figure 2. Results suggest that the mean 
paw edema volume in the normal control (G1) and 
disease control (G2) group was 0.25 ± 0.03 mL and 0.11 ± 
0.02mL, respectively. The levamisole group (G3) showed 
an increased paw volume by 0.24 ± 0.02 mL i.e. 120.5% as 
compared with the G2 group. However, significant 
improved paw volume was found in the experimental 
treated groups by 86.36%, 30.68%, 14.77%, 4.54%, and 
4.55% in the G5, G6, G7, G8, and G9 groups, respectively 
as compared with the disease control (G2) group.  
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Figure 2: Effect of the test formulation on rat paw volume (delayed-type hypersensitivity). G1: Normal control; G2: 
Disease control; G3: Levamisole hydrochloride; G4: Untreated test formulation; G5: Biofield Treated test formulation; 
G6: Biofield Energy Treatment per se to animals (-15 days); G7: Biofield Energy Treated test formulation from day -15; 
G8: Biofield Energy Treatment per se to animals with Biofield Treated test formulation from day -15; and, G9: Biofield 
Energy Treatment per se to animals with the untreated test formulation. 
 
 
Evaluation of hematological parameter 
The effect of the Biofield Treated test formulation on 
various selected hematological parameters are shown in 
Table 1. Results showed that the platelet count was 
significantly increased by 9.22% and 11.96% in the 
untreated test formulation group (G5) and Biofield 
Treated group alone at day -15 (G6), respectively than G2. 
Moreover, hemoglobin level was significantly increased 
by 3.32% and 5.63% in the G6 and Biofield Energy 
Treatment per se to animals with the untreated test 
formulation (G9) groups, respectively as compared to the 
G2 group. Additionally, the level of RBC was increased by 
3.27%, 5.79%, 5.41%, and 5.28% in the Biofield Treated 
test formulation (G4), G6, Biofield Energy Treated test 
formulation at day -15 (G7), and G9 groups, respectively 
as compared to the G2 group. Further, the level of mean 
corpuscle volume (MCV) was increased by 3.77% in the 
Biofield Energy Treatment per se to animals with Biofield 
Treated test formulation from day -15 (G8) group as 
compared to the G2 group. 
 
Group 
RBC 
(106/L) 
Hb 
(gm/dL) 
PCV 
(%) 
MCV 
(fl) 
MCH 
(pg) 
MCHC 
(%) 
Platelet Count 
(thou/mm3) 
RDW-CV 
G1 8.57 ± 0.18 15.59 ± 0.18 45.69 ± 0.58 53.39 ± 0.80 18.24 ± 0.43 34.15 ± 0.43 1023.75 ± 34.56 0.11 ± 0.001 
G2 7.95 ± 0.17 14.75 ± 0.20 43.01 ± 0.88 54.15 ± 0.50 18.61 ± 0.29 34.35 ± 0.35 1111.13 ± 64.34 0.12 ± 0.002 
G3 8.00 ± 0.10 14.74 ± 0.26 43.14 ± 0.75 53.91 ± 0.53 18.43 ± 0.17 34.16 ± 0.12 964.50 ± 70.66 0.12 ± 0.001 
G4 8.21 ± 0.12 15.03 ± 0.19 44.13 ± 0.60 53.80 ± 0.62 18.34 ± 0.23 34.08 ± 0.21 1117.38 ± 54.60 0.12 ± 0.001 
G5 7.89 ± 0.12 14.74 ± 0.23 43.59 ± 0.84 55.28 ± 0.55 18.70 ± 0.21 33.83 ± 0.23 1213.63 ± 78.49 0.13 ± 0.002 
G6 8.41 ± 0.16 15.48 ± 0.18 44.88 ± 0.57 53.43 ± 0.57 18.44 ± 0.29 34.49 ± 0.30 1244.00 ± 36.18 0.12 ± 0.001 
G7 8.38 ± 0.21 15.24 ± 0.22 45.28 ± 0.91 54.11 ± 0.38 18.21 ± 0.22 33.70 ± 0.33 1093.63 ± 59.68 0.12 ± 0.001 
G8 7.77 ± 0.28 14.80 ± 0.35 43.51 ± 1.05 56.19 ± 0.99 19.11 ± 0.34 34.00 ± 0.17 1001.00 ± 122.00 0.12 ± 0.002 
G9 8.37 ± 0.10 15.58 ± 0.19 45.79 ± 0.65 54.69 ± 0.30 18.60 ± 0.14 34.03 ± 0.18 1058.63 ± 55.89 0.13 ± 0.003 
Table 1: Evaluation of hematology parameters of Biofield Energy Treated test formulation in male Sprague Dawley rats. 
 
Data are expressed as the mean ± SEM. G1: Normal 
control; G2: Disease control; G3: Positive control; G4: 
Untreated test formulation; G5: Biofield Treated test 
formulation; G6: Biofield Energy Treatment alone at day -
15 (without test formulation); G7: Biofield Energy Treated 
test formulation at day -15; G8: Biofield Energy Treatment 
per se to animals with Biofield Treated test formulation 
from day -15; and, G9: Biofield Energy Treatment per se to 
animals with the untreated test formulation. 
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Evaluation of biochemical parameter  
Alteration of various biochemical parameters after 
treatment with the test formulation is shown in Table 2. 
The serum was used as matrix for the estimation of 
biochemical parameters viz. magnesium (Mg), blood urea 
nitrogen (BUN), creatinine (CR), uric acid (UA), calcium 
(Ca), phosphorus (P), potassium (K+), sodium (Na+), and 
chloride (Cl-) ion. The level of uric acid (UA) was 
significantly reduced by 64.29% in the Biofield Treated 
test formulation at day -15 (G7) group as compared to the 
disease control (G2) group. The levels of calcium and 
phosphorus were increased by 19.16% and 14.92%, 
respectively in the Biofield Energy Treatment per se to 
animals with the untreated test formulation (G9) group 
compared to the G2 group. The level of magnesium was 
significantly increased by 13.11%, 6.56%, 9.84%, and 
10.66% in the Biofield Energy Treated test formulation 
(G4), G7, Biofield Energy Treatment per se to animals with 
Biofield Treated test formulation from day -15 (G8), and 
G9 groups, respectively compared to the G2 group. 
 
Group 
Magnesium 
(mg/dL) 
Blood Urea 
(mg/dL) 
Creatinine 
(mg/dL) 
Uric Acid 
(mg/dL) 
Calcium 
(mg/dL) 
Phosphorus 
(mg/dL) 
Na+ (Meq/L) K+ (mEq/L) Cl- (mEq/L) 
G1 2.68 ± 0.10 50.28 ± 2.41 0.40 ± 0.04 1.36 ± 0.33 9.44 ± 0.06 9.03 ± 0.49 144.01 ± 0.85 4.66 ± 0.07 98.75 ± 0.73 
G2 2.44 ± 0.09 49.43 ± 3.37 0.33 ± 0.02 1.15 ± 0.32 9.34 ± 0.08 9.05 ± 0.21 145.13 ± 0.65 4.55 ± 0.09 100.75 ± 1.62 
G3 2.71 ± 0.11 50.20 ± 2.76 0.30 ± 0.02 1.01 ± 0.19 9.40 ± 0.13 8.69 ± 0.34 145.75 ± 0.73 4.61 ± 0.11 101.75 ± 1.59 
G4 2.76 ± 0.11 48.08 ± 3.91 0.33 ± 0.02 1.40 ± 0.24 9.45 ± 0.06 8.49 ± 0.23 144.84 ± 0.80 4.75 ± 0.08 99.10 ± 1.09 
G5 2.77 ± 0.13 44.00 ± 2.26 0.35 ± 0.04 1.36 ± 0.10 9.91 ± 0.06 9.80 ± 0.42 144.95 ± 0.38 4.64 ± 0.05 102.00 ± 1.89 
G6 2.36 ± 0.07 51.56 ± 2.06 0.33 ± 0.02 1.19 ± 0.14 9.68 ± 0.09 9.43 ± 0.24 145.65 ± 0.84 4.61 ± 0.04 99.00 ± 0.38 
G7 2.60 ± 0.14 47.50 ± 3.68 0.30 ± 0.00 0.70 ± 0.17 9.44 ± 0.12 9.19 ± 0.51 144.93 ± 0.46 4.69 ± 0.10 101.98 ± 1.47 
G8 2.68 ± 0.09 50.91 ± 2.66 0.30 ± 0.00 1.24 ± 0.16 9.78 ± 0.14 9.86 ± 0.25 146.43 ± 0.55 4.63 ± 0.06 103.13 ± 1.27 
G9 2.70 ± 0.12 51.91 ± 2.17 0.33 ± 0.02 1.63 ± 0.47 11.13 ± 1.07 10.40 ± 0.44 144.44 ± 0.75 4.74 ± 0.08 103.38 ± 1.49 
 
Table 2: Assessment of some essential biochemical constituents of Biofield Treated herbomineral test formulation in 
male Sprague Dawley rats. 
 
Data are expressed as the mean ± SEM. G1: Normal 
control; G2: Disease control; G3: Positive control; G4: 
Biofield Treated test formulation; G5: Untreated test 
formulation; G6: Biofield Treatment alone at day -15 
(without test formulation); G7: Biofield Treated test 
formulation at day -15; G8: Biofield Energy Treatment per 
se to animals with Biofield Treated test formulation from 
day -15; and, G9: Biofield Energy Treatment per se to 
animals with the untreated test formulation. 
 
Discussion 
The humoral immune response data suggest that the 
Biofield Energy Treatment at -day15 had shown 
significant improvement of the antibody titer level as 
compared with the Biofield Energy Treated product. All 
the treatment results with respect to the -day 15 showed 
an improved primary titer values. The findings also 
suggest that the test formulation exhibited a potent 
immunomodulatory effect on humoral mediated 
immunity with improved antibody synthesis under 
inflammatory stimulus. The increase in antibody titer 
values in the Biofield Treated test formulation and 
Biofield Energy Treatment per se clearly states the 
significance of the test formulation in humoral immunity 
modulation. This might involve the production of specific 
antibodies (immunoglobulins) by lymphatic or plasma 
cells after sensitization to specific antigens [33]. It can be 
concluded that the Biofield Treated herbomineral 
formulation may augment the body’s immunity and 
enhance the capacity against various infections like 
bacterial and viral that might lead to enhance the body’s 
immune response. It also suggests that the Biofield 
Energy Treatment per se to the animals might alter some 
biological properties which are responsible for significant 
immunological changes in all the Biofield Energy Treated 
animals. 
 
DTH, a peripheral expression of cell-mediated immunity 
which is influenced by antigen-specific T cells and 
induced by various allergens [34]. These results suggest 
that the Biofield Treated test formulation has significantly 
improved DTH in terms of increased paw volume in rat. 
The increased paw volume might be due to the 
constituents present in the test formulation. Therefore, it 
can be concluded that the constituents present in the test 
formulation are responsible for DTH reaction; however 
the Biofield Energy Healing (The Trivedi Effect®) 
Treatment has significantly enhanced the anti-
inflammatory and immune response as compared with 
the untreated test formulation group.  
 
It was indicated that the Biofield Treated test formulation 
showed more increment of platelets counts than 
untreated formulation; which might be due to the Biofield 
Energy Healing Treatment. Overall, it is indicated that the 
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Biofield Energy Treated test formulation showed better 
platelets counts as compared to both untreated (G4) as 
well as Biofield Treatment group per se. From literature, it 
was reported that ashwagandha prevented 
myelosuppression and increase in platelet count and body 
weight [35]. Study observed that an increased platelet 
count was well matched with the literature findings due 
to the presence of ashwagandha. Rest of the parameters 
such as PCV, MCH, MCHC, and RDW-CV were altered, 
however did not show any significant results as compared 
to the disease control (G2) group. It indicated that the 
Biofield Energy Treatment was unaffected to these 
parameters.  
 
Uric acid is considered as a marker of most of 
inflammatory and immune-related disorders [36]. Here, 
the Biofield Treated test formulation at day -15 (G7) 
showed beneficial effect by significantly reducing the 
concentration of UA than both disease control and 
untreated product. The results might be due to Biofield 
Energy Healing to the novel herbomineral product, which 
could be very helpful in the patients with inflammatory or 
autoimmune disorders like rheumatic arthritis in near 
future. Besides, the levels of magnesium, calcium, and 
phosphorous were improved in the Biofield Treated 
groups with respect to the disease control group. The 
excellent outcomes of Biofield Energy Treated 
formulation might be due to the unique electromagnetic 
radiations of the Biofield Energy Healers during energy 
transmission process. 
 
Conclusion 
The experimental results suggest that Biofield Treatment 
per se and the Biofield Energy Treated test formulation 
have shown significant immunomodulatory action with 
improved primary antibody titer values by 60%, 63.33%, 
33.33%, and 20% in the G6, G7, G8, and G9 groups, 
respectively as compared with the disease control (G2) 
group. Moreover, the secondary antibody titer values in 
the G6, G7, G8, and G9 groups were also increased by 
50%, 37.5%, 37.5%, and 12.5%, respectively, compared to 
the G2 group. Delayed type hypersensitivity data also 
suggest that there was an increased in rats paw volume by 
86.36%, 30.68%, and 14.77% in the G5, G6, and G7 
groups, respectively compared to the G2 group. Besides, 
hematological parameter like platelet counts was 
increased in the G6 group by 11.96% compared to the G2 
group. Biochemical parameters like uric acid level was 
reduced in the G7 group (by 64.29%), increased the levels 
of calcium (by 19.16%) and phosphorous (by 14.92%) 
were increased in the G9 group, compared to the G2 
group. 
 
Further, serum magnesium level was significantly 
increased by 13.11%, 9.84%, and 10.66% in the G4, G8, 
and G9 groups, respectively compared to the G2 group. 
Overall, data suggests that the Biofield Energy Treatment 
(The Trivedi Effect®) per se to the animals and Biofield 
Energy Treated test formulation showed an improved 
immune response as compared with the untreated test 
formulation. Therefore the Biofield Treatment can be 
used to fight against various immuno-related disorders 
such as neutropenia, asplenia, trauma, sickle cell anemia, 
multiple myeloma, chronic lymphoid leukemia, stress, 
aging, etc. Besides, it can also be used for the transplant of 
various organs (kidney, liver, and heart), autoimmune 
disorders (Systemic Lupus Erythematosus, Addison 
Disease, Graves’ Disease, Thyroiditis, Multiple Sclerosis, 
Myasthenia Gravis, Pernicious Anemia, Aplastic Anemia, 
Rheumatoid Arthritis, Sjogren Syndrome, Alopecia Areata, 
Vasculitis, Type 1 Diabetes, Fibromyalgia, Crohn’s Disease, 
Vitiligo, Chronic Fatigue Syndrome Scleroderma, 
Psoriasis), and inflammatory disorders such as 
Diverticulitis, Ulcerative Colitis, Asthma, Alzheimer’s 
Disease, Atherosclerosis, Irritable Bowel Syndrome, 
Parkinson’s Disease Dermatitis, Hepatitis, and stress etc. 
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